NBRV实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Aug 2023 @ 04:00):

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections...

Stats
今日成交量	706 536
平均成交量	13 843.00
市值	4.55M
EPS	$-4.50 ( 2023-08-10 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0722
ATR14	$0.181 (28.73%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-06	Hogan H Michael Iii	Buy	0
2023-06-30	Maggio David	Buy	0
2023-01-29	Gelone Steven P.	Sell	140	Ordinary Shares
2023-01-29	Schroeder Theodore R	Sell	431	Ordinary Shares
2023-01-06	Gelone Steven P.	Sell	5	Ordinary Shares

INSIDER POWER
20.49
Last 98 transactions
Buy: 1 927 900 \| Sell: 612 376

音量相关性

長: 0.06 (neutral)

短: 0.60 (weak)

Signal:(34.114) Neutral

Nabriva Therapeutics PLC 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Nabriva Therapeutics PLC 相关性 - 货币/商品

-0.66
( moderate negative )

-0.25
( neutral )

-0.15
( neutral )

-0.11
( neutral )

0.79
( moderate )

0.14
( neutral )

Nabriva Therapeutics PLC 财务报表

Annual	2022
营收:	$35.67M
毛利润:	$7.09M (19.87 %)
EPS:	$-21.32

FY	2022
营收:	$35.67M
毛利润:	$7.09M (19.87 %)
EPS:	$-21.32

FY	2021
营收:	$28.90M
毛利润:	$15.75M (54.50 %)
EPS:	$-96.24

FY	2020
营收:	$2.86M
毛利润:	$2.10M (73.25 %)
EPS:	$-135.23

Financial Reports:

No articles found.

Nabriva Therapeutics PLC

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.